Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of two dietary supplements—5-hydroxytryptophan (5-HTP), a serotonin precursor, and creatine monohydrate, a compound involved in cellular energy metabolism. This combination is being investigated as an adjunctive treatment for major depressive disorder (MDD), particularly in individuals who have not responded adequately to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). The rationale is that 5-HTP may increase central serotonin synthesis while creatine may enhance brain bioenergetics. Early clinical studies suggest this combination can reduce depressive symptoms when added to standard antidepressant therapy, with good tolerability over short-term use[1][2][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-hydroxytryptophan + creatine monohydrate.